Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 132

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 132
---
 and $0.0149 per warrant.

Holders

As
of February 3, 2025, there were 133 holders of record of our Common Stock and 32 holders
of record of our Public Warrants. The numbers of holders of record do not include for example
a substantially greater number of “street name” holders or beneficial holders
whose securities are held of record by banks, brokers and other financial institutions.

Dividend Policy

We have not paid any cash
dividends to date. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements,
and general financial condition. The payment of any cash dividends will be within the discretion of our Board at such time.

<div align='center'>70

CAPITALIZATION</div>

The following table sets
forth our cash and our capitalization as of September 30, 2024, on:

| ● | an            
 actual basis; |

| ● | on                                                                                            
 an as adjusted basis giving effect to (i) the exercise of 2,462 Preferred Warrants for 2,462  
 shares of Series A Preferred Stock and the receipt of the cash proceeds of such exercises,    
 (ii) the conversion of 3,484 shares of Series A Preferred Stock into 759,369 shares of Common 
 Stock, including the shares of Series A Preferred Stock set forth in clause (i), (iii) the    
 conversion of 213 shares of Series B Preferred Stock into 41,376 shares of Common Stock,      
 (iv) the issuance of 247,914 warrants to purchase shares of Common Stock and (v) the issuance 
 of 436,384 shares of Common Stock pursuant to the Keystone Equity Financing, in each case     
 from October 1, 2024 through January 8, 2025; and                                             |

| ● | on a pro forma basis, giving effect to the adjustments in the preceding                                                                      
 bullet and the issuance and sale of 300,000 shares of Common Stock and 2,251,020 Pre-Funded Warrants in this offering at the public offering 
 price of $1.96 per share, and after deducting placement agent fees and estimated offering expenses payable by us and assuming no exercise    
 of Offered Common Warrants.                                                                                                                  |

All information in this
section gives retroactive effect to the Reverse Stock Split.

You should read this information
in conjunction with our consolidated financial statements and the related notes included elsewhere in this prospectus, the